Richard Auchus, MD, PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Novartis Pharmaceuticals
    Date added:
    06/06/2022
    Date updated:
    06/06/2022
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Neurocrine Biosciences
    Date added:
    06/06/2022
    Date updated:
    06/06/2022
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Spruce Biosciences
    Date added:
    06/06/2022
    Date updated:
    06/06/2022
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Corcept Therapeutics
    Date added:
    06/06/2022
    Date updated:
    06/06/2022
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Diurnal, LTD
    Date added:
    06/06/2022
    Date updated:
    06/06/2022
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Quest Diagnostics
    Date added:
    06/06/2022
    Date updated:
    06/06/2022
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Corcept Therapeutics
    Date added:
    06/06/2022
    Date updated:
    06/06/2022
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Janssen Pharmaceuticals
    Date added:
    06/06/2022
    Date updated:
    06/06/2022
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Novartis Pharmaceuticals
    Date added:
    06/06/2022
    Date updated:
    06/06/2022
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Strongbridge Biopharma/Xeris Pharmaceuticals
    Date added:
    06/06/2022
    Date updated:
    06/06/2022
    Relationship end date:
    12/31/2025

Pages

Return to 2nd Annual UT Southwestern Multidisciplinary Endocrine Tumor Symposium: Mild Autonomous Cortisol Secretion And Primary Aldosteronism (RP2206E)

 

**Disclaimer**

This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.